Cardiff Oncology (CRDF) Receivables (2016 - 2025)
Cardiff Oncology (CRDF) has disclosed Receivables for 15 consecutive years, with $482000.0 as the latest value for Q4 2025.
- Quarterly Receivables fell 58.91% to $482000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $482000.0 through Dec 2025, down 58.91% year-over-year, with the annual reading at $482000.0 for FY2025, 58.91% down from the prior year.
- Receivables hit $482000.0 in Q4 2025 for Cardiff Oncology, up from $254000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.3 million in Q4 2022 to a low of $161000.0 in Q2 2023.
- Historically, Receivables has averaged $531200.0 across 5 years, with a median of $466500.0 in 2024.
- Biggest five-year swings in Receivables: plummeted 70.78% in 2023 and later skyrocketed 212.12% in 2024.
- Year by year, Receivables stood at $535000.0 in 2021, then soared by 137.57% to $1.3 million in 2022, then plummeted by 30.13% to $888000.0 in 2023, then skyrocketed by 32.09% to $1.2 million in 2024, then crashed by 58.91% to $482000.0 in 2025.
- Business Quant data shows Receivables for CRDF at $482000.0 in Q4 2025, $254000.0 in Q3 2025, and $526000.0 in Q2 2025.